A Swiss-based pharmaceutical company said today the study will focus on veterans of the wars in Iraq and Afghanistan.
The company said it hopes the drug, called Nepicastat, will help patients who have lost the ability to accurately assess danger, resulting in a constant sense of alertness.
Some 40,000 U.S. troops have been diagnosed with the disorder since 2003.
The clinical trial will be conducted by researchers at veterans’ medical centers in Tuscaloosa, Alabama; Houston; and Charleston, South Carolina.
Initial results are expected next spring.